Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blinatumomab for Minimal Residual Disease (MRD) in Pre-B Cell Acute Lymphoblastic Leukemia Patients Following Hematopoietic Cell Transplantation: A Canadian, Multicentre Trial

NCT04044560 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT04044560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04044560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blinatumomab for Minimal Residual Disease (MRD) in Pre-B Cell Acute Lymphoblastic Leukemia Patients Following Hematopoietic Cell Transplantation: A Canadian, Multicentre Trial
Lead sponsor
University of British Columbia
Phase
Phase 2
Overall status
Terminated
Start date
September 8, 2020
Completion date
February 2, 2022
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell adult acute lymphoblastic leukemia, minimal residual disease, stem cell leukemia